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N ucleic acid  am plification  tes ting  is th e  p re fe rred  m eth o d  to  
detec t en te rov iru ses an d  H erpesviridae  in  cereb rosp inal fluid, 
b u t clin icians still request v iral cu ltu re . Review o f 22,394 viral 
cu ltu res  o f  cereb rosp inal flu id  sam ples fo u n d  th a t  <0.1%  
recovered no n en te ro v iru s, n o n -H erpesviridae  species, sug­
gesting th a t, w hen nucleic acid  am plification  tes ting  is p e r­
fo rm ed , v iral cu ltu re  m ay have n o  ad d itio n a l benefit.
Nucleic acid amplification testing (NAAT) has become a stan­
dard part of the diagnostic evaluation of viral meningitis and 
meningoencephalitis [I, 2]. NAAT has superior sensitivity for 
the detection of herpes simplex virus (HSV) and enterovirus 
(F.V) in CSF samples, and the rapidity of results can have an 
immediate impact on patient care [2, 3]. However, despite ex­
tensive clinical and laboratory data supporting the use of NAAT 
of CSF samples, clinicians often still request viral culture, with 
the expectation that viruses not specifically targeted by molec­
ular tests might be recovered. Excluding F.V, other viruses com­
monly implicated in CNS infections (e.g., HSV, varicella zoster 
virus, cytomegalovirus, and West Nile virus) are either poorly 
recovered from culture or better diagnosed by alternative m eth­
ods (e.g., NAAT and serological testing) [ 1, 4-6]. We examined 
the utility of CSF culture to recover viruses not detected by 
routine NAAT, and we assessed the potential cost savings of 
eliminating viral CSF culture as a routine laboratory practice.
M ethods. Results of viral culture from CSF samples sub­
mitted between 2 December 1994 and 1 December 2005 were 
retrospectively reviewed. Samples submitted between 2 January 
2000 and 4 December 2005 were analyzed as a subset to deter­
mine the average time required to obtain F.V and HSV results
Received 19 July 2006; accepted 30 August 2006; electronically published 7 November 
2006.
Reprints or correspondence- Dr Christopher R. Polage, ARUP Laboratories, Inc., 500 Chipeta 
Way, Salt Lake City, UT 84108 (polagec@aruplab.com).
Clinical Infectious Diseases 2006;43:1578-9
© 2006 by the Infectious Diseases Society of America. All rights reserved.
10584838/2006/4312-0008S15.00
by culture and PCR and to compare the relative rates of detection 
for these viruses when performed using the same specimen.
Comprehensive viral cultures were performed by shell vial 
method, including 5 cell lines (rhesus monkey kidney, buffalo 
green monkey, A549, MRC-5, + /— rhabdomyosarcoma [April— 
September]) provided by ARUP Reagent Lab and Diagnostic 
Hybrids. Shell vials were monitored for viral cytopathic effect 
for at least 10 days. When requested, early antigen detection for 
cytomegalovirus was performed at 24 and 48 h. Cytopathic effect, 
virus type, and virus subtype were confirmed by virus-specific 
immunofluorescent antibodies (Chemicon International and 
Dako North America) when indicated. Cytopathic effect consis­
tent with HSV was confirmed by polyclonal immunoperoxidase 
staining (ARUP Reagent Lab) and subtypedby HSV type-specific 
monoclonal DFA (Trinity Biotech). HSV PCR was performed by 
in-house assay using validated primer sets and real-time probe 
detection. HSV PCR assays with positive results with late crossing 
thresholds were performed again prior to reporting of results by 
standard laboratory protocol. F.V PCR was performed by in­
house assay, as described elsewhere [7].
Average annual and total study period costs for viral culture 
from CSF samples were calculated using an average laboratory 
charge for CSF viral culture of $52, which did not change 
significantly during the study period.
Results. During the 11 -year period, viruses were recovered 
from 1270 (5.7%) of 22,394 viral cultures of CSF samples. The 
viruses isolated included 1249 (98.4%) F.V, 16 (1.3%) HSV, 3 
(0.2%) cytomegalovirus, 1 (0.08%) varicella zoster virus, and
1 (0.08%) adenovirus. Samples originated from 33 states, with 
all major geographic regions of the United States represented.
For the subset analysis comparing the performance of PCR 
and culture, both culture and F.V PCR were performed for 929 
CSF samples. O f these, 246 samples had positive results overall, 
with 124 (50.4%) of the samples having positive results by both 
methods, 4 (1.6%) having positive culture results only, and 118 
(48.0%) having positive F.V PCR results only. There were 1290 
CSF samples for which both culture and HSV PCR were per­
formed. O f these, 9 samples were HSV positive, and HSV was 
detected for all 9 (100%) only by PCR.
The mean time required to obtain a completed culture result 
positive for FV was 169 h {n =  995), a time period that was 7.2 
times longer than the average time required to obtain a positive 
result from F.V PCR (24 h; n =  7085). Similarly, the average 
time required to obtain a completed culture result positive for 
HSV was 149 h (n =  14), a period 3.9 times longer than the 
mean time required to obtain a PCR result positive for HSV (39
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h; n =  2478). The mean length of time required to obtain a 
negative result by culture was 277 h (n =  16,887), a period that 
was 12 times longer than that required to obtain a PCR result 
negative for EV (22 h; n =  17,023) or HSV (21 h; n =  64,565).
During the past 3 years, our laboratory received 3501 (in 
2003), 3952 (in 2004), and 3443 (in 2005) requests for viral 
culture from CSF samples, resulting in a mean annual health 
care expenditure of $188,864 per year. For the 11-year period 
examined, the estimated health care expenditure resulting from 
the 22,394 viral CSF cultures performed was $1,164,488.
Discussion. Nucleic acid amplification-based methods have 
emerged as the recognized standard [1, 2] for the detection of 
EV and Herpesviridae from CSF samples and are increasingly 
requested as part of the diagnostic work-up of viral meningitis 
and meningoencephalitis for both imm unocompetent and im­
munocompromised hosts. Yet, clinicians still commonly request 
viral culture of CSF samples in lieu of or as an adjunct to 
NAAT. One possible explanation for this practice is physicians’ 
expectations that viral culture may recover viruses in addition 
to EV or Herpesviridae. O ur 11-year review of viral cultures 
from CSF samples found that 99.6% of positive cultures re­
covered either EV or HSV The remaining positive cultures 
(0.4%) isolated viruses (cytomegalovirus, varicella zoster virus, 
and adenovirus) that NAAT, if performed, would have detected 
more rapidly and with greater sensitivity [1, 2, 4, 5]. Although 
we were not able to obtain clinical history for the cultures 
positive for viruses other than EV and HSV, we suspect that 
the clinical presentations or predisposing conditions of these 
patients (e.g., congenitally infected newborns, solid-organ or 
hematopoetic stem cell transplant recipients, patients with lym­
phoma, and patients with advanced HIV disease) would lead 
experienced physicians to consider these viruses in their dif­
ferential diagnosis and to specifically request molecular testing 
for them. Clearly, NAAT remains more expensive than culture 
(e.g., the approximate charges are $140 for EV PCR, $64 for 
HSV PCR, and $52 for viral culture), bu t with its superior 
sensitivity and faster results, NAAT generates more-meaningful 
results with a potentially greater impact on patient care [2, 3].
In this study, the yield of viral culture may have been reduced 
by the delay in specimen transport to a reference laboratory and 
might be better at laboratories with the opportunity to inoculate 
fresh specimens. Studies that have specifically examined this issue 
suggest that, for HSV and EV, recovery is generally adequate up 
to 72 h after collection when the sample is transported in ap­
propriate media [8, 9], although poor recovery of HSV at low 
titers may be a relevant exception that further emphasizes the 
value of PCR [9]. We also acknowledge that clinical circumstances 
may arise for which performance of viral culture from CSF sam­
ples is indicated. For example, when rare but cultivable causes 
of viral meningoencephalitis (e.g., influenza, parainfluenza, mea­
sles, and mumps) are clinically suspected for which NAAT is
unavailable, viral culture can serve as a useful adjunctive test [10, 
11]. In fact, mumps, a common cause of meningitis and en­
cephalitis in the prevaccine era, has recently resurfaced in several 
prominent outbreaks in the United Kingdom and the United 
States [11]. However, it should be emphasized that serological 
testing and NAAT have emerged as the diagnostic standard for 
the majority of recognized viral causes of meningitis and en­
cephalitis for which diagnosis by culture-based methods is either 
not routinely possible (e.g., arboviruses) or not indicated because 
of poor sensitivity (e.g., HSV) [1, 2, 5, 6],
Although limited to the experiences of 1 laboratory, we dem­
onstrate the potential costs incurred from routine performance 
of these cultures and, importantly, corroborate the previous 
findings of others that viral culture for EV and HSV is both 
insensitive and associated with marked diagnostic delay [2]. We 
conclude that routine submission of CSF samples for viral cul­
ture specifically to recover viruses not ordinarily detected by 
NAAT is costly and provides minimal, if any, additional benefit. 
We recommend that viral culture of CSF samples be eliminated 
as a routine laboratory practice.
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